Loading...
Eculizumab in atypical haemolytic–uraemic syndrome allows cessation of plasma exchange and dialysis
Disorders in complement regulation are a major cause of atypical haemolytic–uraemic syndrome (aHUS). Eculizumab, a monoclonal antibody targeting complement C5 and blocking the terminal complement cascade, should theoretically be useful in this disease, particularly when associated with specific comp...
Na minha lista:
| Udgivet i: | Clin Kidney J |
|---|---|
| Main Authors: | , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Oxford University Press
2012
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4400463/ https://ncbi.nlm.nih.gov/pubmed/26069744 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ndtplus/sfr174 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|